Malignant hyperthermia: pharmacology of triggering
Author:
Open Access
- 30 May 2011
- journal article
- review article
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 107 (1) , 48-56
Abstract
Over the past 50 yr, many drugs have been implicated as triggers of malignant hyperthermia (MH), a potentially fatal pharmacogenetic disorder of skeletal muscle calcium regulation. This review discusses the potent inhalation agents as the principal triggers and evidence that the modern agents, desflurane, sevoflurane, and isoflurane, can cause florid MH reactions in the same way as halothane but also are associated with reactions whose onset is delayed for several hours into anaesthesia. There is evidence that the triggering of MH by drugs is dose-dependent but the minimum dose that will trigger the condition is unknown. This has implications for the preparation of anaesthetic machines when used for known or suspected MH patients. While succinylcholine enhances the response of potent inhalation anaesthetics, its role as an inherent trigger of the condition is controversial. Non-depolarizing neuromuscular blocking drugs appear to protect against the development of MH and this may be by blocking excitation-coupled calcium entry—a recently described route of skeletal muscle calcium entry that may also explain the mechanism of the effect of succinylcholine in MH. Another mechanism for extracellular calcium influx, store-operated calcium entry, is activated in MH muscle and may explain how a triggered reaction is sustained. Finally, reports of drugs that have been implicated as additional triggers of MH over the past 10 yr are discussed.Keywords
This publication has 74 references indexed in Scilit:
- Preparation of Modern Anesthesia Workstations for Malignant Hyperthermia–susceptible PatientsAnesthesiology, 2011
- Store-operated Ca2+ Entry in Malignant Hyperthermia-susceptible Human Skeletal MuscleJournal of Biological Chemistry, 2010
- A malignant hyperthermia–inducing mutation in RYR1 (R163C): alterations in Ca2+ entry, release, and retrograde signaling to the DHPRJournal of General Physiology, 2010
- Clinical Presentation, Treatment, and Complications of Malignant Hyperthermia in North America from 1987 to 2006Anesthesia & Analgesia, 2010
- Recognizing and managing a malignant hyperthermia crisis: guidelines from the European Malignant Hyperthermia GroupBritish Journal of Anaesthesia, 2010
- Calcium-Induced Calcium Release in Skeletal MusclePhysiological Reviews, 2009
- Mutations inRYR1in malignant hyperthermia and central core diseaseHuman Mutation, 2006
- Phosphodiesterase-III-inhibition with amrinone leads to contracture development in skeletal muscle preparations of malignant hyperthermia susceptible swineEuropean Journal of Anaesthesiology, 2005
- Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing?European Journal of Human Genetics, 2003
- The anaesthetic management of the malignant hyperthermia susceptible parturientCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1986